Telomerase expression in human breast cancer with and without lymph node metastases

American Journal of Clinical Pathology

Volumn 107, Issue 5, 1997, Pages 542-547

  Nawaz, Samia ^a   Hashizumi, Tanya L ^a   Markham, Neil E ^a   Shroyer, A Laurie ^b   Shroyer, Kenneth R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Fibroadenoma; Telomerase; Telomeric repeat amplification protocol

Indexed keywords

TELOMERASE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST FIBROADENOMA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; PRIORITY JOURNAL;

EID: 0030893243     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/107.5.542     Document Type: Article

References (19)

1. Zakian VA. Telomerase: beginning to understand the end. Science. 1995;270:1601-1607.
2. Greider CW, Blackburn EH. Telomeres, telomerase and cancer. Sci Am. 1996;274:92-97.
3. Harley CB, Villeponteau B. Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev. 1995;5:249-255.
4. Chong L, van Steensel B, Broccoli D, et al. A human telomeric protein. Science. 1995;270:1663-1667.
5. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
6. Fisher B, Slack NH. Number of lymph nodes examined and the prognosis of breast carcinoma. Surg Gynecol Obstet. 1970;131:79-88.
7. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
8. Layfield LJ, Conlon DH, Dodge R, et al. Immunohistochemically determined estrogen and progesterone receptor levels: a comparison of three antibodies with the ligand-binding assay. Breast J. 1996;2:141-149.
9. Parl FF. Estrogen receptor for determination in human breast cancer. In: Stefanini M, Gorstein F, Fink LM, eds. Progress in Clinical Pathology. New York, NY: Grune and Stratton; 1984;9:155-179.
10. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1,409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11:359.
11. Scarff RW, Toroloni H. Histologic Typing of Breast Tumors. Geneva, Switzerland: World Health Organization; 1968:13-20.
12. Tavassoli FA: Pathology of the Breast. Stamford, Conn: Appleton & Lange; 1992:336.
13. Rosner BA. Fundamentals of Biostatistics. Boston, Mass: Duxbury Press; 1982:225-253, 308-317.
14. Mehta CR, Patel NR. A network algorithm for performing Fisher's exact test in r x c contingency tables. J Am Stat Assoc. 1983;78:427-434.
15. Hiyama E, Gollahon L, Kataoka T, et al. Telomerase activity in human breast tumors. J Natl Cancer Inst. 1996;88:116-122.
16. Kim N, Levitt D, Huang G, et al. Correlation of telomerase with prognostic indicators of breast cancer. Proc Am Assoc Cancer Res. 1996;37:3852.
17. Bednarek A, Sahin A, Aldaz CM. Telomerase in human breast cancer. Proc Am Assoc Cancer Res. 1996;37:3855.
18. Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol. 1996;16:53-65.
19. Azzopardi JG. Problems in Breast Pathology. Philadelphia, Pa: Saunders; 1979:39-56.